drugset / Trial / NCT07245953
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy of HT-101 injection combined with HT-102 injection.
Timeline
- Start
- 2025-11-05
- Primary completion
- 2027-02
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HT-101 | Unknown | — | Subcutaneous |
| Subject | HT-102 | Monoclonal antibody | — | Subcutaneous |